Articles from Target RWE

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of more than 110,000 patients, the largest real-world comparative effectiveness evaluation of patients with established atherosclerotic cardiovascular disease (ASCVD) treated with Repatha® (evolocumab). The results reveal that treatment with Repatha is associated with a 20% lower risk in composite major cardiovascular events (MACE) of myocardial infarction (MI), stroke and coronary revascularization and a 29% lower risk of composite MACE of MI, stroke and cardiovascular death at four years compared to patients not treated with Repatha.

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced it will have multiple presentations focused on the testing and related outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, taking place November 7-11, 2025 in Washington, D.C.

Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, announced the appointment of Sriram Krishnan, Ph.D. as the company’s new Chief Product Officer. A recognized leader in healthcare AI and digital health, Krishnan joins the company with decades of experience in building and commercializing products with patient impact.

Target RWE today announced the appointment of Ed Seguine as chief executive officer (CEO). Target RWE is a longitudinal data company that generates high-quality real-world datasets and plans to reimagine evidence across multiple therapeutic areas, with liver disease as a flagship. In January, Highlander Health, a firm advancing evidence generation and personalized health care for the new era of medical innovation, acquired Target RWE. Led by industry veterans Amy Abernethy, M.D., Ph.D., and Brad Hirsch, M.D., Target RWE marks the first acquisition under Highlander Health Partners, a division of Highlander Health.